Stéphane Champiat
The University of Texas MD Anderson Cancer Center(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, CAR-T cell therapy research, Lung Cancer Treatments and Mutations, Occupational and environmental lung diseases
Most-Cited Works
- → Immune-related adverse events with immune checkpoint blockade: a comprehensive review(2016)2,094 cited
- → A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study(2018)1,203 cited
- → Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1(2016)1,185 cited
- → Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination(2016)1,087 cited
- → Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper(2015)885 cited
- → Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy(2018)725 cited
- → Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab(2015)641 cited
- → Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors(2018)520 cited
- → Novel patterns of response under immunotherapy(2019)496 cited
- → Intratumoural administration and tumour tissue targeting of cancer immunotherapies(2021)456 cited